Drug Profile
BC 001
Alternative Names: BC001Latest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator University of Southern California
- Developer NANTCANCERSTEMCELL
- Class Antineoplastics
- Mechanism of Action Hypoxia-inducible factor 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 23 Aug 2023 Discontinued - Preclinical for Solid tumours in USA (Parenteral)
- 28 Aug 2019 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 19 Oct 2016 NantCancerStemCell plans a phase I trial for Solid tumours (Globavir pipeline, October 2016)